drugset / Trial / NCT00398463

Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance

NCT00398463 ↗

Phase 4 Completed 263 enrolled Università degli Studi di Ferrara
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate whether adding tirofiban, administered at high bolus dose on top of aspirin and clopidogrel will lead to a lower rate of periprocedural myocardial infarction after percutaneous coronary intervention in elective patients presenting with aspirin and/or clopidogrel resistance.

Timeline

Start
2006-05
Primary completion
2008-07
Completion
2011-05

Outcome

Met primary endpoint

paper 20.4% (n=27) in the tirofiban group compared with 35.1% (n=46) in the placebo group (relative risk, 0.58; 95% confidence interval, 0.39 to 0.88; P=0.009). PMID 19528337 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirofiban Other / unclassified — Other

Indications

No indication recorded.